MPT-0E028 is under clinical development by Formosa Pharmaceuticals and currently in Phase I for Metastatic Liver Cancer. According to GlobalData, Phase I drugs for Metastatic Liver Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the MPT-0E028 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MPT-0E028 overview
MPT-0E028 is under development for the treatment of solid tumors including colorectal cancer, hepatic cancer, pancreatic cancer, non-small cell lung cancer and lymphoma, leukemias. It is administered orally. The drug candidate acts by targeting histone deacetylase.
Formosa Pharmaceuticals overview
Formosa Pharmaceuticals is a biopharmaceutical company. It utilizes nanoparticle technology platform to develop drugs for indications of ophthalmology, oncology, and anti-infectives. The company’s product pipeline includes APP13007 drug candidate to treat inflammation and pain after ocular surgery; TSY-0110, a biosimilar of antibody-drug conjugate, ado-trastuzumab emtansine (Kadcyla) for breast cancer; and TSY-0210 for novel disease applications. Formosa Pharmaceuticals is also developing APP13002 to treat infectious eye diseases; and MPT0E028 for treatment of oncology and fibrosis. The company develops and commercializes drugs in collaboration with AimMax Therapeutics, Taipei Medical University, Eyenovia, and CGE Healthcare, among others. Formosa Pharmaceuticals is headquartered in Taipei, Taiwan.
For a complete picture of MPT-0E028’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
